eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Neonatology

Kernicterus: Differential Diagnoses & Workup

Author: Shelley C Springer, MD, MBA, MSc, FAAP, JD LS-3, Clinical Instructor, Department of Pediatrics, University of Wisconsin; Neonatologist, Pediatrix Medical Group; Assistant Clinical Professor, Department of Pediatrics, University of North Texas Science Center; Assistant Clinical Professor, Department of Pediatrics, Texas A & M University
Coauthor(s): David J Annibale, MD, Associate Professor, Director of Neonatology, Director of Fellowship Training Program in Neonatal-Perinatal Medicine, Department of Pediatrics, Medical University of South Carolina
Contributor Information and Disclosures

Updated: Sep 30, 2008

Differential Diagnoses

Fetal Alcohol Syndrome
Hypothyroidism
Head Trauma
Meningitis, Bacterial
Hearing Impairment
Neonatal Sepsis
Herpes Simplex Virus Infection
Periventricular Leukomalacia
Hyperammonemia

Other Problems to Be Considered

Cerebral palsy
Hypoxic-ischemic brain injury in the newborn
Sepsis

Workup

Laboratory Studies

  • Hematologic studies: Hematologic laboratory evaluation is the cornerstone of evaluation of the baby with hyperbilirubinemia. Although jaundice can be appreciated clinically, observation alone is not a reliable method to assess the severity or estimate risk factors for the infant.
  • Total and direct bilirubin: Quantitative measurement of total and direct bilirubin levels should be undertaken in every baby at risk for significant hyperbilirubinemia or kernicterus. Total bilirubin measures the aggregate of all forms of bilirubin in the serum. The direct fraction measures the amount of conjugated bilirubin. Subtraction of the direct fraction from the total yields the calculated indirect bilirubin, or the unconjugated form. Remember that the indirect fraction is composed of bound bilirubin, free bilirubin, and lumirubin, as well as many other clinically unidentifiable isomers if the baby is receiving phototherapy.6 Only the free bilirubin is available to cross the blood-brain barrier and has the potential to cause neurotoxicity; if and how the presence of other isomers modulates this process is unclear. Attempts to measure the amount of bound albumin or to estimate the bound fraction from measures of serum albumin have not proved to be clinically useful.
    • Serial measurements may be necessary to track the evolution of hyperbilirubinemia; frequency of measurements depends on the baby's gestational age, chronologic age, risk factors, and other clinical characteristics.
    • In infants who were reported to the US kernicterus registry, total serum bilirubin levels ranged from 20.7-59.9 mg/dL at the time of presentation with the classic physical signs of kernicterus.2
    • Every baby with hyperbilirubinemia should have a direct fraction measured at least once to rule out direct hyperbilirubinemia. Direct hyperbilirubinemia in the neonate is defined as a direct fraction of more than 2 mg/dL or more than one third of the total bilirubin concentration and is always pathologic. Subsequently, if the hyperbilirubinemia is established as the indirect type, obtaining a direct fraction with every measurement is unnecessary unless the hyperbilirubinemia develops after the expected time frame for typical neonatal hyperbilirubinemia.
    • With the advent of early discharge (before the physiologic peak of serum bilirubin) some clinicians are advocating universal bilirubin measurements in all babies prior to discharge. Nomograms have been published that estimate a baby's risk of disease based on measured levels of bilirubin. One nomogram that assessed the risk of critical hyperbilirubinemia in babies leaving the hospital within 24-48 hours of birth adjusted for gestational age and postnatal age in hours (see Media file 3).7
  • Blood type: The baby's blood type should be determined and compared with that of the mother. Mothers with type O blood may have circulating antibodies to other red cell antigens that can cross the placenta and cause hemolytic disease in a baby with a different blood type, such as blood type A or B. Similarly, mothers who are Rh negative may have antibody to the Rh antigen if they have not been treated with RhoGAM. Antibody to the Rh antigen causes the most fulminant type of hemolytic hyperbilirubinemia, termed erythroblastosis fetalis in its most severe form. ABO incompatibility can cause significant hemolysis as well. Minor antigens on the baby's RBC are also susceptible to immune-mediated hemolysis from maternally acquired antibody but usually to a lesser extent than the major antigens. Documentation of maternal antibody status during the pregnancy should alert the caretaker about potential risk for hemolytic disease and hyperbilirubinemia.
  • Reticulocyte count: Babies typically have reticulocyte counts higher than older infants and adults. However, significant elevation in the neonate's reticulocyte count (>7 mg/dL) can indicate the presence of an ongoing hemolytic process.
  • Direct Coombs test: This test assays for antibody on the RBC membrane. A positive result indicates that antibodies are attached to the RBC, placing it at risk for immune-mediated destruction. This is a qualitative test, so a positive result does not suggest the amount of antibody or the degree of hemolysis. However, pairing these results with the reticulocyte count can provide some idea of the severity of the process. This test, although reliable, does not have 100% sensitivity. Because false-negative results do occur, repeating a test with an initial negative result is not unreasonable if the clinical course supports an ongoing hemolytic process. In a many cases of ABO incompatibility, direct Coombs test findings may be negative. Therefore, an elution test should be performed to demonstrate anti-A or anti-B antibodies in the serum.
  • CBC count: A CBC with manual differential should always be included in the evaluation of a newborn with jaundice. Measurement of the hemoglobin and hematocrit can be helpful to determine if ongoing hemolysis severe enough to cause anemia is present. The peripheral smear inspection is particularly valuable because it may reveal large amounts of nucleated RBCs, suggesting active reticulocytosis; it may reveal abnormally shaped RBCs in the case of hereditary membrane defects such as spherocytosis and elliptocytosis or marked ovalocytosis in the case of hemolytic disease of the newborn. Babies with sepsis can develop hyperbilirubinemia, and, although not conclusive, normal total WBC count and manual differential can be reassuring in a healthy-appearing baby with hyperbilirubinemia.
  • Serum electrolytes: Breastfed babies are known to normally develop higher levels of serum bilirubin than their formula-fed counterparts. However, with the trend toward earlier discharge, most breastfed babies are being discharged home before breastfeeding is well established, and a concomitant increase in the number of infants readmitted to the hospital in the first week of life with hypernatremic dehydration has occurred. Many of these babies are also significantly hyperbilirubinemic, and the resurgence of kernicterus from its previous virtual obsolescence is being attributed partly to this situation. Therefore, assessing serum sodium, potassium, chloride, bicarbonate, BUN, and creatinine levels is essential; initiate treatment as appropriate.
  • Lumbar puncture: In the initial evaluation of hyperbilirubinemia, sepsis may be included in the differential diagnosis. If so, collection of spinal fluid for culture and cell count should be considered to rule out meningitis. If the baby is having neurologic symptoms, cerebral spinal fluid (CSF) evaluation is imperative; depending on the baby's symptoms, expanding the evaluation beyond the normal aerobic bacterial culture may be prudent. If, on the other hand, the baby is vigorous and well-appearing with isolated hyperbilirubinemia as the only symptom (ie, sepsis is not likely to be the cause of the hyperbilirubinemia), a spinal tap may not be necessary.
  • Transcutaneous bilirubin measurement: Numerous devices that transcutaneously measure total serum bilirubin levels have become commercially available. These devices have been tested in babies of varying ethnicities, skin pigmentations, and gestational ages. Correlation with serum bilirubin measurements is generally good. Although this approach is not recommended to replace the criterion standard of serum measurement, it may be a useful adjunct to the clinical management of hyperbilirubinemia in the term and/or preterm infant.

Imaging Studies

  • In the acute phase of bilirubin encephalopathy, neuroimaging has no major diagnostic benefit. However, it can help rule out other diagnoses, particularly in the absence of profound hyperbilirubinemia.
  • Head ultrasonography (HUS): This modality is particularly well suited to the neonate because it is painless, portable, and noninvasive; also, the neonatal brain is easily imaged through the fontanelles. Ultrasonography is not helpful in diagnosing acute bacterial encephalopathy; however, other entities, such as intraventricular hemorrhage or parenchymal abnormalities, can be ruled out.
  • CT scanning: CT scanning has little place in the evaluation of the neonatal brain. The subtle abnormalities often present in the neonatal period are not well visualized by CT scanning, and false-negative findings are not uncommon.
  • MRI: Previously, the neuronal damage characteristic of kernicterus was thought to only be identifiable on histologic examination postmortem. However, experience has revealed that MRI can be used to depict characteristic bilateral symmetric high-intensity signals in the globus pallidus on both T1-weighted and T2-weighted images in patients surviving with chronic bilirubin encephalopathy (see Media file 4). The usefulness and cost-effectiveness of this modality in the diagnosis of more subtle forms of bilirubin-induced neurologic dysfunction (BIND) remains to be fully elucidated.

Other Tests

  • Brainstem auditory evoked response (BAER): Hearing impediment is the most common sequela of bilirubin toxicity. Impairment may be subtle and may not be clinically apparent until the baby manifests delayed language acquisition. To maximize the baby's long-term neurologic functioning, early identification of any degree of hearing loss is important so that early developmental assessment and intervention can be initiated in a timely fashion. Serial assessments of hearing function may be necessary.

Histologic Findings

  • On macroscopic examinations, characteristic yellow staining can be readily observed in fresh or frozen sections of the brain obtained within 7-10 days after the initial bilirubin insult. The regions most commonly involved include the basal ganglia, particularly the globus pallidus and subthalamic nucleus; the hippocampus; the substantia nigra; cranial nerve nuclei, including the oculomotor, cochlear, and facial nerve nuclei; other brainstem nuclei, including the reticular formation and the inferior olivary nuclei; cerebellar nuclei, particularly the dentate; and the anterior horn cells of the spinal cord.
  • Neuronal necrosis occurs later and results in the clinical findings consistent with chronic bilirubin encephalopathy. Histologically, this appears as cytoplasmic vacuolation, loss of Nissl substance, increased nuclear density with haziness to the nuclear membrane, and pyknotic nuclei (see Media file 5).

More on Kernicterus

Overview: Kernicterus
Differential Diagnoses & Workup: Kernicterus
Treatment & Medication: Kernicterus
Follow-up: Kernicterus
Multimedia: Kernicterus
References

References

  1. Johnson L, Brown AK. A pilot registry for acute and chronic kernicterus in term and near-term infants. Pediatrics. Sept 1999;104:(3):736.

  2. Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr. Apr 2002;140(4):396-403. [Medline].

  3. Ebbesen F. Recurrence of kernicterus in term and near-term infants in Denmark. Acta Paediatr. Oct 2000;89(10):1213-7. [Medline].

  4. British Paediatric Surveillance Unit. Surveillance of severe hyperbilirubinaemia in the newborn commenced the May. BPSU Quarterly Bulletin. 2003;11(2):2.

  5. Sgro M, Campbell D, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ. Sep 12 2006;175(6):587-90. [Medline].

  6. McDonagh AF. Ex uno plures: the concealed complexity of bilirubin species in neonatal blood samples. Pediatrics. Sep 2006;118(3):1185-7. [Medline].

  7. AAP. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. Jul 2004;114(1):297-316. [Medline].

  8. [Best Evidence] Mehta S, Kumar P, Narang A. A randomized controlled trial of fluid supplementation in term neonates with severe hyperbilirubinemia. J Pediatr. 2005;147 (6):781 - 5. [Medline].

  9. Sanpavat S. Exchange transfusion and its morbidity in ten-year period at King Chulalongkorn Hospital. J Med Assoc Thai. May 2005;88(5):588-92. [Medline].

  10. Badiee Z. Exchange transfusion in neonatal hyperbilirubinaemia: experience in Isfahan, Iran. Singapore Med J. May 2007;48(5):421-3. [Medline].

  11. [Best Evidence] Gourley GR, Li Z, Kreamer BL, Kosorok MR. A controlled, randomized, double-blind trial of prophylaxis against jaundice among breastfed newborns. Pediatrics. Aug 2005;116(2):385-91. [Medline].

  12. Dennery PA. Metalloporphyrins for the treatment of neonatal jaundice. Curr Opin Pediatr. Apr 2005;17(2):167-9. [Medline].

  13. Kaplan M, Kaplan E, Hammerman C, et al. Post-phototherapy neonatal bilirubin rebound: a potential cause of significant hyperbilirubinaemia. Arch Dis Child. Jan 2006;91(1):31-4. [Medline].

  14. Martins BM, de Carvalho M, Moreira ME, Lopes JM. Efficacy of new microprocessed phototherapy system with five high intensity light emitting diodes (Super LED). J Pediatr (Rio J). May-Jun 2007;83(3):253-8. [Medline].

  15. Romagnoli C, Zecca E, Papacci P, Vento G, Girlando P, Latella C. Which phototherapy system is most effective in lowering serum bilirubin in very preterm infants?. Fetal Diagn Ther. 2006;21(2):204-9. [Medline].

  16. van Kaam AH, van Beek RH, Vergunst-van Keulen JG, et al. Fibre optic versus conventional phototherapy for hyperbilirubinaemia in preterm infants. Eur J Pediatr. Feb 1998;157(2):132-7. [Medline].

  17. Keren R, Bhutani VK, Luan X, Nihtianova S, Cnaan A, Schwartz JS. Identifying newborns at risk of significant hyperbilirubinaemia: a comparison of two recommended approaches. Arch Dis Child. Apr 2005;90(4):415-21. [Medline].

  18. Keren R, Luan X, Friedman S, Saddlemire S, Cnaan A, Bhutani VK. A comparison of alternative risk-assessment strategies for predicting significant neonatal hyperbilirubinemia in term and near-term infants. Pediatrics. Jan 2008;121(1):e170-9. [Medline].

  19. Raghavan K, Thomas E, Patole S, Muller R. Is phototherapy a risk factor for ileus in high-risk neonates?. J Matern Fetal Neonatal Med. Aug 2005;18(2):129-31. [Medline].

  20. Ahlfors CE, Wennberg RP. Bilirubin-albumin binding and neonatal jaundice. Semin Perinatol. Oct 2004;28(5):334-9. [Medline].

  21. AlOtaibi SF, Blaser S, MacGregor DL. Neurological complications of kernicterus. Can J Neurol Sci. Aug 2005;32(3):311-5. [Medline].

  22. Bader D, Yanir Y, Kugelman A, et al. Induction of early meconium evacuation: is it effective in reducing the level of neonatal hyperbilirubinemia?. Am J Perinatol. Aug 2005;22(6):329-33. [Medline].

  23. Barefield ES, Dwyer MD, Cassady G. Association of patent ductus arteriosus and phototherapy in infants weighting less than 1000 grams. J Perinatol. Sep-Oct 1993;13(5):376-80. [Medline].

  24. Bhutani VK, Donn SM, Johnson LH. Risk management of severe neonatal hyperbilirubinemia to prevent kernicterus. Clin Perinatol. 2005;32 (1):125 - 39, vii. [Medline].

  25. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. Jan 1999;103(1):6-14. [Medline][Full Text].

  26. Bhutani VK, Johnson LH, Jeffrey Maisels M, et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol. Oct 2004;24(10):650-62. [Medline].

  27. Cashore WJ. Bilirubin and jaundice in the micropremie. Clin Perinatol. Mar 2000;27(1):171-9, vii. [Medline].

  28. Drummond GS, Kappas A. Chemoprevention of severe neonatal hyperbilirubinemia. Semin Perinatol. Oct 2004;28(5):365-8. [Medline].

  29. Gartner LM. Neonatal jaundice. Pediatr Rev. Nov 1994;15(11):422-32. [Medline].

  30. Juretschke LJ. Kernicterus: still a concern. Neonatal Netw. Mar-Apr 2005;24(2):7-19. [Medline].

  31. Kaplan M, Hammerman C. Understanding severe hyperbilirubinemia and preventing kernicterus: adjuncts in the interpretation of neonatal serum bilirubin. Clin Chim Acta. Jun 2005;356(1-2):9-21. [Medline].

  32. Kumral A, Genc S, Genc K, et al. Hyperbilirubinemic serum is cytotoxic and induces apoptosis in murine astrocytes. Biol Neonate. 2005;87(2):99-104. [Medline].

  33. MacMahon JR, Stevenson DK, Oski FA. Physiologic jaundice. In: Taeusch, Ballards, eds. Avery's Disease of the Newborn. 7th ed. Philadelphia, PA: Saunders; 1998:1003-7.

  34. Maisels MJ. Jaundice. In: Avery, Fletcher, eds. Neonatology, Pathophysiology and Management of the Newborn. 5th ed. Philadelphia, PA: Lippincott; 1999:765-819.

  35. Petersen JR, Okorodudu AO, Mohammad AA, et al. Association of transcutaneous bilirubin testing in hospital with decreased readmission rate for hyperbilirubinemia. Clin Chem. 2005;51 (3):481 - 2. [Medline][Full Text].

  36. Pezzati M, Biagiotti R, Vangi V, et al. Changes in mesenteric blood flow response to feeding: conventional versus fiber-optic phototherapy. Pediatrics. Feb 2000;105(2):350-3. [Medline][Full Text].

  37. Rubegni P, Cevenini G, Sbano P, et al. Cutaneous colorimetric evaluation of serum concentrations of bilirubin in healthy term neonates: a new methodological approach. Skin Res Technol. Feb 2005;11(1):70-5. [Medline].

  38. Sanpavat S, Nuchprayoon I. Noninvasive transcutaneous bilirubin as a screening test to identify the need for serum bilirubin assessment. J Med Assoc Thai. Oct 2004;87(10):1193-8. [Medline].

  39. Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND). J Perinatol. Jan 2005;25(1):54-9. [Medline].

  40. Taketomo CK, Hodding JH, Draus DM. Pediatric Dosage Handbook. 10th ed. Cleveland, OH: Lexi-Comp, Inc; 2003.

  41. Volpe JJ. Bilirubin and Brain Injury: Neurology of the Newborn. 3rd ed. Philadelphia, PA: WB Saunders; 1995:490-514.

  42. Watchko JF. Vigintiphobia revisited. Pediatrics. Jun 2005;115(6):1747-53. [Medline].

  43. Willems WA, van den Berg LM, de Wit H, Molendijk A. Transcutaneous bilirubinometry with the Bilicheck in very premature newborns. J Matern Fetal Neonatal Med. Oct 2004;16(4):209-14. [Medline].

Further Reading

Keywords

kernicterus, acute bilirubin encephalopathy, chronic postkernicteric bilirubin encephalopathy, chronic bilirubin encephalopathy, profound pathologic hyperbilirubinemia, bilirubin-induced neurologic dysfunction, BIND, jaundice, hemolytic disease, glucose-6-phosphate dehydrogenase deficiency, hereditary spherocytosis, retrocollis, opisthotonus, athetosis, chorea, hearing loss, delayed language acquisition, birth trauma, Crigler-Najjar syndrome, polycythemia, smoking, hemolytic disease of the newborn, pyruvate kinase deficiency, thalassemia, cephalohematoma, subgaleal hemorrhage, peripheral ecchymoses, hypoalbuminemia, liver transplantation, Arias syndrome, Gilbert syndrome, galactosemia, hypothyroidism, acidosis, breastfeeding jaundice, breast milk jaundice

Contributor Information and Disclosures

Author

Shelley C Springer, MD, MBA, MSc, FAAP, JD LS-3, Clinical Instructor, Department of Pediatrics, University of Wisconsin; Neonatologist, Pediatrix Medical Group; Assistant Clinical Professor, Department of Pediatrics, University of North Texas Science Center; Assistant Clinical Professor, Department of Pediatrics, Texas A & M University
Shelley C Springer, MD, MBA, MSc, FAAP, JD LS-3 is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, and Minnesota Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

David J Annibale, MD, Associate Professor, Director of Neonatology, Director of Fellowship Training Program in Neonatal-Perinatal Medicine, Department of Pediatrics, Medical University of South Carolina
David J Annibale, MD is a member of the following medical societies: American Academy of Pediatrics and National Perinatal Association
Disclosure: Nothing to disclose.

Medical Editor

Oussama Itani, MD, FAAP, FACN, Clinical Associate Professor of Pediatrics and Human Development, Michigan State University; Medical Director, Department of Neonatology, Borgess Medical Center
Oussama Itani, MD, FAAP, FACN is a member of the following medical societies: American Academy of Pediatrics, American College of Nutrition, American College of Physician Executives, and American Heart Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

David A Clark, MD, Chairman, Professor, Department of Pediatrics, Albany Medical College
David A Clark, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Pediatric Society, Christian Medical & Dental Society, Medical Society of the State of New York, New York Academy of Sciences, and Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina
Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American Medical Women's Association, American Public Health Association, American Society for Bone and Mineral Research, American Society for Clinical Nutrition, Massachusetts Medical Society, National Perinatal Association, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD, Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine
Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.